Cancer Program

The next big questions in cancer research.

Loi S, Settleman J, Joyce JA, et al. The next big questions in cancer research. Cell. 2023;186(8):1523-1527. doi:10.1016/j.cell.2023.01.037.PubMed Google Scholar DOI

Targeting TBK1 to overcome resistance to cancer immunotherapy.

Sun Y, Revach O-Y, Anderson S, et al. Targeting TBK1 to overcome resistance to cancer immunotherapy. Nature. 2023. doi:10.1038/s41586-023-05704-6.PubMed Google Scholar DOI

In vivo CRISPR screens reveal the landscape of immune evasion pathways across cancer.

Dubrot J, Du PP, Lane-Reticker SK, et al. In vivo CRISPR screens reveal the landscape of immune evasion pathways across cancer. Nat Immunol. 2022;23(10):1495-1506. doi:10.1038/s41590-022-01315-x.PubMed Google Scholar DOI

Phosphate dysregulation via the XPR1-KIDINS220 protein complex is a therapeutic vulnerability in ovarian cancer.

Bondeson DP, Paolella BR, Asfaw A, et al. Phosphate dysregulation via the XPR1-KIDINS220 protein complex is a therapeutic vulnerability in ovarian cancer. Nat Cancer. 2022. doi:10.1038/s43018-022-00360-7.PubMed Google Scholar DOI

Unannotated proteins expand the MHC-I-restricted immunopeptidome in cancer.

Ouspenskaia T, Law T, Clauser KR, et al. Unannotated proteins expand the MHC-I-restricted immunopeptidome in cancer. Nat Biotechnol. 2022;40(2):209-217. doi:10.1038/s41587-021-01021-3.PubMed Google Scholar DOI

PPM1D mutations are oncogenic drivers of de novo diffuse midline glioma formation.

Khadka P, Reitman ZJ, Lu S, et al. PPM1D mutations are oncogenic drivers of de novo diffuse midline glioma formation. Nat Commun. 2022;13(1):604. doi:10.1038/s41467-022-28198-8.PubMed Google Scholar DOI

An In Vivo CRISPR Screening Platform for Prioritizing Therapeutic Targets in AML.

Lin S, Larrue C, Scheidegger NK, et al. An In Vivo CRISPR Screening Platform for Prioritizing Therapeutic Targets in AML. Cancer Discov. 2022;12(2):432-449. doi:10.1158/2159-8290.CD-20-1851.PubMed Google Scholar DOI

Somatic and germline genomic alterations in very young women with breast cancer.

Waks AG, Kim D, Jain E, et al. Somatic and germline genomic alterations in very young women with breast cancer. Clin Cancer Res. 2022. doi:10.1158/1078-0432.CCR-21-2572.PubMed Google Scholar DOI

Towards a Better Understanding of Antibody-Drug Conjugates in Urothelial Carcinoma.

Labaki C, Bakouny Z, Sonpavde G, Choueiri TK, Van Allen EM. Towards a Better Understanding of Antibody-Drug Conjugates in Urothelial Carcinoma. Eur Urol Oncol. 2022. doi:10.1016/j.euo.2022.01.004.PubMed Google Scholar DOI

Implementation of a prostate cancer-specific targeted sequencing panel for credentialing of patient-derived cell lines and genomic characterization of patient samples.

Stover EH, Oh C, Keskula P, et al. Implementation of a prostate cancer-specific targeted sequencing panel for credentialing of patient-derived cell lines and genomic characterization of patient samples. Prostate. 2022. doi:10.1002/pros.24305.PubMed Google Scholar DOI